Menu Contents

Pipeline

The Research Team at Boryung Pharmaceutical aims to lead the Future of the Pharmaceutical Industry

  • Pipeline Introduction

    After 12 years of research, Boryung Pharmaceutical succeeded in developing the first domestic hypertension drug, ‘Kanarb’. By independently carrying out all the necessary steps – candidate material excavation, raw material synthesis, formulation research, a non-clinical trial, and clinical trial phases one, two and three – Boryung Pharmaceutical has established our very own capability for drug development. Boryung Pharmaceutical was established based on its drug development capabilities. We are expanding our scope of research into a variety of areas to develop drugs for cancer treatment, antibiotics, NCE(New Chemical Entity) and gene therapy that focuses on cardiovascular and other major diseases, vaccines and other biopharmaceuticals. We are particularly focused on the development of the Kanarb Value-Up Pipeline. In addition, we are focusing on the research and development of new API(Active Pharmaceutical Ingredient) products aimed at the globalization of API.

Kanarb Value-up Pipeline

The ‘Kanarb Value-up Pipeline’ consists of products that allow for the integrative treatment of patients with hypertension associated with the majority of metabolic diseases. These products are all NCE and IMDs and developed in-house.
Development of the ‘Kanarb Value-up Pipeline’ will not only increase sales in the single and composite drug market, but will also strengthen the global competitiveness of Kanarb through the global license out.

(Jan. 2021 standard)

Kanarb Value-up Pipeline
Classification Project Name Treatment for Discovery Pre-clinical Phase 1 Phase 2 Phase 3
IMD BR1010 Hypertension

Kanarb Value-up Pipeline

(Jan. 2021 standard)

Kanarb Value-up Pipeline
IMD

BR1010

Hypertension

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

Pipeline

We are strengthening our R&D portfolio to focus on antibiotics and major diseases such as cancer and cardiovascular disease (CV). We will add a new pipeline that centers on diseases whose markets are expected to grow in the future. We are also focusing on developing NCE and incrementally modified drugs (IMD) to fulfill unmet needs, while working to discover new drugs on the cutting edge of bio-tech.

(Jan. 2021 standard)

Main Pipeline
Classification Project Name Treatment for Discovery Pre-clinical Phase 1 Phase 2 Phase 3
NCE BR2002 Cancer
BR2006 Cancer
BR2007 Cancer
NBE VT-EBV-201 Cancer
NCE
(external)
Lurbinectedin Cancer
Plitidepsin Cancer
PeproStat™ Haemostasis
ReadyFlow™ Haemostasis
IMD BR4001 Alzheheimer's disease
BR4002 Alzheheimer's disease
I1903 Smoking Cessation
BR9006 Benign Prostatic Hyperplasia
I1907 Diabetes
BR3003 Diabetes

Pipeline

(Jan. 2021 standard)

Main Pipeline
NCE

BR2002

Cancer

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR2006

Cancer

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR2007

Cancer

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
NBE

VT-EBV-201

Cancer

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
NCE(external)

Lurbinectedin

Cancer

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

Plitidepsin

Cancer

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

PeproStat™

Haemostasis

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

ReadyFlow™

Haemostasis

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
IMD

BR4001

Alzheimer’s disease

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR4002

Alzheheimer's disease

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

I1903

Smoking Cessation

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR9006

Benign Prostatic Hyperplasia

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

I1907

Diabetes

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3

BR3003

Diabetes

Discovery Pre-
clinical
Phase 1 Phase 2 Phase 3
TOP